

Prima BioMed – Fast Facts

Listings

Australian Securities Exchange (ASX), NASDAQ

Stock Codes

ASX: PRR, PRRO (options), NASDAQ: PBMD

Issued Capital – Ordinary shares

2.06 B (approx. as of 29 December 2015)

Market Capitalisation

A\$88.6 M (approx. as of 14 March 2016)

Issued ADR's

21.83 M (approx. as of 31 January 2016)

Cash Position

A\$25.5 M (approx. as of 31 December 2015)

Board of Directors

Ms Lucy Turnbull, AO Chairman (Non-Executive)

Mr Albert Wong Deputy Chairman (Non-Executive)

Mr Marc Voigt Executive Director, Chief Executive Officer

Dr Russell J Howard Non-Executive Director

Mr Pete A Meyers Non-Executive Director

Senior Management

Prof Dr Frédéric Triebel Chief Scientific Officer & Chief Medical Officer

Ms Deanne Miller General Counsel & Company Secretary

Company Overview

Prima BioMed (ASX:PRR, NASDAQ: PBMD) is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products.

With operations based in Australia, Germany and France, Prima BioMed is dedicated to bringing innovative treatment options to market for patients and to maximizing value for shareholders.


Prima's core technologies are based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response.

Our lead product, IMP321 is in clinical development for the treatment of a range of cancer indications.

A number of our products have been partnered with large pharmaceutical partners including Novartis, GSK, Eddingpharm and Neopharm.

In addition, Prima has significantly developed infrastructure for a cell-based therapy manufacturing platform and taken CVac™, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission.

Prima BioMed is listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US (ADR's).



Contact






Headquarters

Level 12, 95 Pitt Street,
Sydney, NSW 2000, Australia

enquiries@primabiomed.com.au
partnering@primabiomed.com.au

www.primabiomed.com.au

Pipeline

Partner	Portfolio	Indication	Preclinical	PhI	PhIIa	PhIIb	Status
WW Prima (ex China: Eddingpharm)	IMP321	Metastatic Breast Cancer					Phase IIb trial began Oct 2015 MOA: APC activator used in chemo-immunotherapy combination
WW Prima (ex China: Eddingpharm)		Immuno-Immuno Combination Therapy in Melanoma					Phase I trial began Jan 2016 MOA: APC activator + checkpoint inhibitor
WW GSK	IMP731	Autoimmune Disease					Phase I trial began Jan 2015 Data expected in 2016 MOA: LAG-3 depleting antibody
WW Novartis	IMP701	Cancer					Phase I trial began Aug 2015 Data expected in 2017 MOA: Blocking LAG-3 antibody
WW Prima (ex Israel: Neopharm)	CVac™	Ovarian Cancer					Phase IIb completed Seeking partnership for future development MOA: Autologous dendritic cell vaccine (antigen: MUC-1)


Lead Technology: LAG-3

LAG-3 stands for Lymphocyte Activation Gene-3 (LAG-3 or CD223). This protein is encoded by the LAG-3 gene in humans and is involved in the regulation of T cells.

The LAG-3 protein has a dual mechanism of action and controls the signaling between T cells and antigen presenting cells (APC's).

Lead Product: IMP321

First in class APC activator used as chemo-immunotherapy



IMP321 is a recombinant protein consisting of a dimer of LAG-3 that has been engineered to be soluble rather than expressed on the surface of cells.

It is a first-in-class antigen presenting cell (APC) activator, which has been proven to induce sustained immune responses in cancer patients when used at low dose as a cancer vaccine adjuvant or used at higher doses to get a systemic effect (i.e. general APC activation).

In addition it has been shown to be safe and well tolerated.

IMP321 binds with high affinity to MHC (major histocompatibility complex) class II molecules on APC, leading to APC activation and then T cell activation/proliferation.

Forward looking statements: Any forward looking statements in this fact sheet have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed Ltd.'s control.